Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. For pharmaceutical firms, watching lucrative patents on their top-selling drugs expire has long been part of the business cycle. There’s enormous pressure to find ways of covering the shortfall.. gfx Most companies sell a hit product for as long as customers want it.